Molecular Therapeutics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
Cancer Signaling and Epigenetics Program, Fox Chase Cancer Center, Philadelphia, Pennsylvania, USA.
J Biol Chem. 2022 Sep;298(9):102367. doi: 10.1016/j.jbc.2022.102367. Epub 2022 Aug 11.
Methylthioadenosine phosphorylase (MTAP) is a key enzyme in the methionine salvage pathway that converts the polyamine synthesis byproduct 5'-deoxy-5'-methylthioadenosine (MTA) into methionine. Inactivation of MTAP, often by homozygous deletion, is found in both solid and hematologic malignancies and is one of the most frequently observed genetic alterations in human cancer. Previous work established that MTAP-deleted cells accumulate MTA and contain decreased amounts of proteins with symmetric dimethylarginine (sDMA). These findings led to the hypothesis that accumulation of intracellular MTA inhibits the protein arginine methylase (PRMT5) responsible for bulk protein sDMAylation. Here, we confirm that MTAP-deleted cells have increased MTA accumulation and reduced protein sDMAylation. However, we also show that addition of extracellular MTA can cause a dramatic reduction of the steady-state levels of sDMA-containing proteins in MTAP+ cells, even though no sustained increase in intracellular MTA is found because of catabolism of MTA by MTAP. We determined that inhibition of protein sDMAylation by MTA occurs within 48 h, is reversible, and is specific. In addition, we have identified two enhancer-binding proteins, FUBP1 and FUBP3, that are differentially sDMAylated in response to MTAP and MTA. These proteins work via the far upstream element site located upstream of Myc and other promoters. Using a transcription reporter construct containing the far upstream element site, we demonstrate that MTA addition can reduce transcription, suggesting that the reduction in FUBP1 and FUBP3 sDMAylation has functional consequences. Overall, our findings show that extracellular MTA can inhibit protein sDMAylation and that this inhibition can affect FUBP function.
甲基硫腺苷磷酸化酶(MTAP)是甲硫氨酸补救途径中的关键酶,可将多胺合成副产物 5'-脱氧-5'-甲基硫腺苷(MTA)转化为甲硫氨酸。MTAP 的失活,通常通过纯合缺失,在实体瘤和血液恶性肿瘤中均有发现,是人类癌症中最常见的遗传改变之一。先前的工作表明,MTAP 缺失的细胞会积累 MTA,并含有较少的具有对称二甲基精氨酸(sDMA)的蛋白质。这些发现导致了这样的假设,即细胞内 MTA 的积累抑制了负责大量蛋白质 sDMA 化的蛋白精氨酸甲基转移酶(PRMT5)。在这里,我们证实 MTAP 缺失的细胞中 MTA 积累增加,蛋白质 sDMA 化减少。然而,我们还表明,即使由于 MTAP 对 MTA 的分解代谢而未发现细胞内 MTA 的持续增加,细胞外 MTA 的添加也可以导致 sDMA 含有蛋白质的稳态水平显着降低。我们确定 MTA 通过抑制蛋白 sDMA 化发生在 48 小时内,是可逆的,并且是特异性的。此外,我们已经鉴定出两种增强子结合蛋白 FUBP1 和 FUBP3,它们对 MTAP 和 MTA 的反应存在差异 sDMA 化。这些蛋白质通过位于 Myc 和其他启动子上游的远上游元件位点起作用。使用包含远上游元件位点的转录报告构建体,我们证明 MTA 加可减少转录,表明 FUBP1 和 FUBP3 的 sDMA 化减少具有功能后果。总体而言,我们的发现表明细胞外 MTA 可以抑制蛋白质 sDMA 化,并且这种抑制可以影响 FUBP 功能。